Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade D 108.0 1.80% 1.91
CELG closed up 1.8 percent on Monday, December 11, 2017, on approximately normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CELG trend table...

Date Alert Name Type % Chg
Dec 11 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Dec 11 New Uptrend Bullish 0.00%
Dec 11 Upper Bollinger Band Walk Other 0.00%
Dec 11 Multiple of Ten Bearish Other 0.00%
Dec 11 Wide Bands Range Expansion 0.00%
Dec 11 Above Upper BB Strength 0.00%
Dec 11 Gapped Up Strength 0.00%
Dec 11 Up 3 Days in a Row Strength 0.00%
Dec 8 Weak + Overbought Other 1.80%
Dec 8 Wide Bands Range Expansion 1.80%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 147.17
52 Week Low 94.55
Average Volume 8,271,639
200-Day Moving Average 124.9913
50-Day Moving Average 114.3188
20-Day Moving Average 103.1505
10-Day Moving Average 103.424
Average True Range 2.9288
ADX 37.87
+DI 29.58
-DI 22.56
Chandelier Exit (Long, 3 ATRs ) 102.0236
Chandelier Exit (Short, 3 ATRs ) 107.2264
Upper Bollinger Band 107.1204
Lower Bollinger Band 99.1806
Percent B (%b) 1.11
BandWidth 7.697297
MACD Line -1.8295
MACD Signal Line -3.1957
MACD Histogram 1.3662
Fundamentals Value
Market Cap 84.49 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 33.44
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 113.24
Resistance 3 (R3) 113.59 112.20 112.36
Resistance 2 (R2) 112.20 110.87 112.02 112.07
Resistance 1 (R1) 110.10 110.04 109.41 109.75 111.78
Pivot Point 108.71 108.71 108.36 108.53 108.71
Support 1 (S1) 106.61 107.38 105.92 106.26 104.22
Support 2 (S2) 105.22 106.55 105.04 103.93
Support 3 (S3) 103.12 105.22 103.64
Support 4 (S4) 102.77